Maureen Whitsett1, Jane Wilcox2, Amy Yang3, Lihui Zhao3, Mary Rinella4, Lisa B VanWagner3,4. 1. Gastroenterology, New York University, New York, New York. 2. Divison of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 3. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 4. Divison of Gastroenterology & Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Abstract
BACKGROUND & AIMS: Nonalcoholic steatohepatitis (NASH) is associated with increased cardiovascular disease. Atrial fibrillation is a prominent risk marker for underlying cardiovascular disease with a prevalence of 2% in patients <65 years old. Atrial fibrillation prevalence in NASH is unknown. We sought to assess the prevalence and impact of atrial fibrillation on healthcare utilization in NASH. METHODS: Patients were identified from a tertiary care centre Electronic Database from 2002 to 2015. International Classification of Diseases 9 (ICD9) codes identified comorbidities and atrial fibrillation. Descriptive statistics were used to compare characteristics between patients with NASH with and without atrial fibrillation. RESULTS: Of 9108 patients with ICD9 diagnosis of NASH, 215 (2.3%, mean age 57 years, 32% male) had biopsy-proven NASH. Atrial fibrillation prevalence was 4.6%. Patients with NASH and atrial fibrillation had a higher prevalence of heart failure (54.5% vs 8.8%, P < 0.001) and cerebrovascular (27.3% vs 2.0%, P < 0.001) or vascular disease (54.5% vs 13.2%, P = 0.002), compared to NASH without atrial fibrillation. All patients with NASH and atrial fibrillation had a CHA2DS2VASc score ≥2 indicating high stroke risk and need for anticoagulation. Eight of 10 patients were eligible for anticoagulation and 5 of 8 (62.5%) received appropriate therapy. CONCLUSION: Atrial fibrillation prevalence is two-fold higher in patients with NASH compared to the general population. Patients with NASH have a high risk of stroke; however, many do not receive appropriate guideline-directed therapy. Future studies are needed to identify whether guideline-based management of atrial fibrillation in NASH reduces cardiovascular morbidity and mortality.
BACKGROUND & AIMS:Nonalcoholic steatohepatitis (NASH) is associated with increased cardiovascular disease. Atrial fibrillation is a prominent risk marker for underlying cardiovascular disease with a prevalence of 2% in patients <65 years old. Atrial fibrillation prevalence in NASH is unknown. We sought to assess the prevalence and impact of atrial fibrillation on healthcare utilization in NASH. METHODS:Patients were identified from a tertiary care centre Electronic Database from 2002 to 2015. International Classification of Diseases 9 (ICD9) codes identified comorbidities and atrial fibrillation. Descriptive statistics were used to compare characteristics between patients with NASH with and without atrial fibrillation. RESULTS: Of 9108 patients with ICD9 diagnosis of NASH, 215 (2.3%, mean age 57 years, 32% male) had biopsy-proven NASH. Atrial fibrillation prevalence was 4.6%. Patients with NASH and atrial fibrillation had a higher prevalence of heart failure (54.5% vs 8.8%, P < 0.001) and cerebrovascular (27.3% vs 2.0%, P < 0.001) or vascular disease (54.5% vs 13.2%, P = 0.002), compared to NASH without atrial fibrillation. All patients with NASH and atrial fibrillation had a CHA2DS2VASc score ≥2 indicating high stroke risk and need for anticoagulation. Eight of 10 patients were eligible for anticoagulation and 5 of 8 (62.5%) received appropriate therapy. CONCLUSION:Atrial fibrillation prevalence is two-fold higher in patients with NASH compared to the general population. Patients with NASH have a high risk of stroke; however, many do not receive appropriate guideline-directed therapy. Future studies are needed to identify whether guideline-based management of atrial fibrillation in NASH reduces cardiovascular morbidity and mortality.
Authors: Peter J Zimetbaum; Amit Thosani; Hsing-Ting Yu; Yan Xiong; Jay Lin; Prajesh Kothawala; Matthew Emons Journal: Am J Med Date: 2010-05 Impact factor: 4.965
Authors: Riikka Lautamäki; Ronald Borra; Patricia Iozzo; Markku Komu; Terho Lehtimäki; Marko Salmi; Sirpa Jalkanen; K E Juhani Airaksinen; Juhani Knuuti; Riitta Parkkola; Pirjo Nuutila Journal: Am J Physiol Endocrinol Metab Date: 2006-02-14 Impact factor: 4.310
Authors: Robby Nieuwlaat; S Bertil Olsson; Gregory Y H Lip; A John Camm; Günter Breithardt; Alessandro Capucci; Joan G Meeder; Martin H Prins; Samuel Lévy; Harry J G M Crijns Journal: Am Heart J Date: 2007-06 Impact factor: 4.749
Authors: Neal S Parikh; Insu Koh; Lisa B VanWagner; Mitchell S V Elkind; Neil A Zakai; Mary Cushman Journal: J Stroke Cerebrovasc Dis Date: 2021-04-16 Impact factor: 2.677